Intranet PAC-CI
FR EN
PAC-CI Logo PAC-CI Contact us
PAC-CI Logo PAC-CI
Contact us

Blue November: PAC-CI mobilizes for men's health and prostate cancer screening

Terminé

A phase IIb, noncomparative, open-label, randomized trial evaluating the efficacy and tolerability of three first-line antiretroviral regimens, combining tenofovir-emtricitabine or lamivudine with zidovudine, or with lopinavir/ritonavir or raltegravir, in adults infected with HIV-2 in West Africa

A randomized, noncomparative, Phase IIb, open-label trial evaluating the efficacy and tolerability of three first-line antiretroviral regimens, combining tenofovir-emtricitabine or lamivudine with zidovudine, or with lopinavir/ritonavir or raltegravir, in adults infected with HIV-2 in West Africa
FIT-2 project logo

Project Details

Participating Countries

  • Burkina Faso
  • Ivory Coast
  • Guinea (Conakry)
  • Senegal
  • Togo

Research Team

The research team has not yet been filled in for this project.

Collaborate with us

We are open to partnerships with international research institutions and doctoral students.

Research Request

Estimated response time: 3-5 business days.

Keywords

OUR PROJECTS
Exploration

Discover other projects

Tous les projets
En valorisation

RaDAR

  • Operations research
  • Togo (EVT, ACS), Côte d'Ivoire (Bouaké, SAS)
  • 30 months